Podcasts about Wojciech

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Główny nurt polskiego ruchu narodowego zrósł się z katolicyzmem niespełna sto lat temu i aż po dziś dzień odwołuje się do koncepcji nacjonalizmu chrześcijańskiego. Wynika to m.in. z faktu, że religia katolicka – zarówno w pierwszych dziesięcioleciach XX w., jak i w czasach współczesnych – na ogół pozytywnie odnosi się do faktu istnienia narodów. Na pytanie, na czym polega rola narodów w Bożej ekonomii zbawienia, stara odpowiedzieć się teologia narodu. Pozostałe artykuły możesz czytać na

Ecoutez Christophe Hondelatte dévoiler la personnalité de Wojciech Janowski. En 2014, il est consul de Pologne à Monaco et il a commandité l'assassinat de sa belle-mère, Hélène Pastor. Une riche femme d'affaire monégasque qui pèse plus de 12 milliards d'euros. Wojciech Janowski a avoué puis s'est rétracté. Il est passé des ors et des honneurs des palais à l'isolement d'une cellule de prison.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Druga niedziela Adwentu / „Uczeń – Misjonarz” – rekolekcje adwentowe / Ewangelia Mt 3, 1-12

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

Więcej WARTOŚCIOWYCH TREŚCI: https://linkedin.com/in/radoslawwyrzykowski Sprawdź WĄSKIE GARDŁO TWOJEJ KARIERY: https://subscribepage.io/waskiegardlo

Learn how dreams help us process trauma with our guest Gdansk Professor Wojciech Owczarski​ who studies the dreams of Auschwitz survivors, modern Ukrainian refugees, and nursing home residents. He finds that dreams help us cope with trauma, adapt to new life situations, and feel optimistic for a better future. Nightmares help us deal with unresolved waking life issues and to integrate past traumas. A short clip from our conversation can be found here: After the break we take two calls. One from Kathy from Corona CA who is wondering about how best to introduce new members into her long-running group. The second call is from Ryan from Maryland who asks whether the prisoners at Auschwitz ever had revenge dreams. BIO. Wojciech Owczarski, PhD, is a professor of humanities and teaches literature and cultural studies at the University of Gdansk, Poland. He is the author of seven monographs on dreams and on literature. The most recent one is devoted to the dreams of the prisoners of the Auschwitz concentration camp and is called Dreaming in Auschwitz. https://www.cambridgescholars.com/product/978-1-5275-9040-3 This show, episode number 339, was recorded during a live broadcast on November 29, 2025 at KSQD.org, community radio of Santa Cruz. Intro and outro music by Mood Science. Ambient music new every week by Rick Kleffel. Archived music can be found at Pandemiad.com. Many thanks to Rick for also engineering the show and to Erik Nelson for answering the phones. SHARE A DREAM FOR THE SHOW or a question or enquire about being a guest on the podcast by emailing Katherine Bell at katherine@ksqd.org. Follow on FB, IG, LI, & YT @ExperientialDreamwork #thedreamjournal. To learn more or to inquire about exploring your own dreams go to ExperientialDreamwork.com. The Dream Journal aims to: Increase awareness of and appreciation for nightly dreams. Inspire dream sharing and other kinds of dream exploration as a way of adding depth and meaningfulness to lives and relationships. Improve society by the increased empathy, emotional balance, and sense of wonder which dream exploration invites. A dream can be meaningful even if you don’t know what it means. The Dream Journal is produced at and airs on KSQD Santa Cruz, 90.7 FM. Catch it streaming LIVE at KSQD.org 10-11am Pacific Time on Saturdays. Call or text with your dreams or questions at 831-900-5773 or email at onair@ksqd.org. Podcasts are available on all major podcast platforms the Monday following the live show. The complete KSQD Dream Journal podcast page can be found at ksqd.org/the-dream-journal/. Closed captioning is available on the YouTube version of this podcast and an automatically generated transcript is available at Apple Podcasts within 24 hours of posting. Thanks for being a Dream Journal listener! Available on all major podcast platforms. Rate it, review it, subscribe, and tell your friends.

In this episode, I sit down with Wojciech Kaszycki — serial entrepreneur, business angel behind 19+ ventures, and the mind behind both Mobilium and BTCS.Wojciech shares how he went from building one of Poland's earliest e‑commerce platforms to pioneering fintech and crypto infrastructure. We explore why his teams focus on building real, regulated bridges between traditional finance and digital assets — not just hype.We dig into how Mobilium plans to let you use Bitcoin as collateral to spend or borrow against, and how BTCS builds a treasury + validator network to bring yield and Web3 services to a wider audience.He also gives practical advice for founders and investors: why a crowded “yes” may be a warning sign — and why sometimes it's the weird, rejected ideas that deserve to be built.If you care about honest, long-term crypto infrastructure and what it takes to build it — this one's for you.It would mean a lot if you can leave a review of this podcast on Apple Podcasts or Spotify — and share this podcast with a friend. Be a guest on the podcast or contact us - https://www.web3pod.xyz/Key Learnings 00:00:10If your idea gets a unanimous “yes” from friends — that may be a red flag. Lack of skepticism could mean low barriers to entry and limited upside. 00:03:00My path: from building Poland's “Amazon‑like” e‑commerce to fintech and eventually entering crypto — bridging traditional finance with digital assets. 00:06:00With Mobilium, we don't just offer a crypto card — we hold real lending licenses so users can borrow against their Bitcoin without selling it. 00:11:00Mobilium's revenue comes from service fees on on‑ramps/off‑ramps, interchange fees from cards, and interest on crypto‑collateral loans. 00:13:00When building products — don't just build what you think is best. Test with real users. But beware: too many opinions can derail focus. 00:18:00BTCS combines a crypto treasury, staking/validator infrastructure, and smart yield strategies — aiming to grow with the value of crypto, not just fiat. 00:22:00Key metrics for BTCS: monthly reward ratio (yield vs net asset value) and compound growth of net asset value per share. 00:28:00Sometimes you're just early — don't be afraid to fail. If your vision holds, the market may catch up later.Connecthttps://www.mobilum.com/enhttps://x.com/Mobilumofficialhttps://x.com/wkaszyckihttps://www.linkedin.com/company/mobilumcom/https://www.linkedin.com/in/wojciechkaszycki/DisclaimerNothing mentioned in this podcast is investment advice. Please do your own research.Be a guest on the podcast or contact us - https://www.web3pod.xyz/

Jego prace zainspirowały twórcę bijącej rekordy popularności „Diuny”, swoje obrazy wystawiał na całym świecie, w tym w Paryżu, na słynnej Wieży Eiffla, doceniają go nie tylko artyści i miłośnicy sztuki, ale także wybitni naukowcy. Wojciech Siudmak, jest jednym z najbardziej znanych współczesnych polskich artystów, który możliwość tworzenia i przekazywania swoich wartości, nazywa przywilejem. Zainspirowany fizyką i nieskończonością wszechświata, stał się głównym przedstawicielem realizmu fantastycznego. Choć od blisko 60 lat mieszka we Francji, pielęgnuje pamięć o polskich korzeniach, szczególnie o bolesnych losach rodzinnego Wielunia. W Drogowskazach, opowiadał o przyszłości sztuki, swojej twórczej pasji oraz fascynacji kosmosem. Jego prace można oglądać na wystawie „Dialog wewnętrzny” w Galerii To Tuart, której właściciel, Marek Duchnowski, opowiadał o odbieraniu sztuki i piękna. Do wysłuchania rozmowy zaprasza Aleksandra Galant.

„Big Techy chcą Europy bez regulacji. USA wykorzystują przewagę i naciskają”W rozmowie z Radiem Wnet dr Wojciech Świder, ekonomista z Uniwersytetu Ekonomicznego w Poznaniu, ocenił, że unijne rozporządzenie AI Act powstało, by chronić obywateli, ale jego wdrażanie jest blokowane, głównie przez interesy amerykańskich gigantów technologicznych.Unia Europejska próbuje się bronić przed zagrożeniami. To bardzo dobre. Natomiast strona amerykańska bardzo mocno nas naciska, żebyśmy tego nie robili. Wykorzystują swoją przewagę i mają mocne karty, żeby nam zabraniać bronienia się przed tymi zagrożeniami– wskazał.Świder podkreślał, że USA stosują nacisk polityczno-gospodarczy, by zablokować europejskie ograniczenia dotyczące sztucznej inteligencji, bo na deregulacji najbardziej zarabiają Big Techy.Deepfake'i bez kontroli. „Granica między prawdą a syntetykiem właściwie zniknęła”Regulacje miały m.in. zobowiązać platformy do oznaczania materiałów wygenerowanych przez AI. To jednak, jak mówił Świder, praktycznie nie działa.Widzimy już dziś bardzo realistyczne materiały wideo, które nie są oznaczane. Ludzie, nie tylko starsi, nie są w stanie odróżnić, co jest syntetyczne, a co nagrane w naszym świecie– zauważył.Sytuację pogorszyło pojawienie się nowych, bardzo zaawansowanych generatorów wideo.Nowe narzędzia sprawiły, że granica już praktycznie się zatarła. Jesteśmy zalewani filmami, których nie da się odróżnić od rzeczywistości– mówił ekspert.Według Świdra prawo istnieje, ale nie jest egzekwowane, a internet pozostaje globalny i pełen treści tworzonych poza UE, czyli poza unijnym nadzorem.„Amerykanie lobbowali, żeby złagodzić AI Act. Chcą, żeby Big Tech zarabiał u nas na danych”Kolejna część rozmowy dotyczyła presji ze strony USA, które mają duży wpływ na kierunek polityki europejskiej.Pojawiły się informacje, że Amerykanie bardzo mocno lobbują, aby niektórych zapisów AI Act nie implementować, niektóre wycofać, inne złagodzić. Chodzi o to, żeby Big Techy mogły bardzo łatwo wejść na europejski rynek i zarabiać na naszych danych– zaznaczał. Jak tłumaczył Świder, Big Techy robią to z prostego powodu: zyski z AI będą kosmiczne.Big Tech zarabia na chaosie. Meta nawet do 10 proc. przychodów czerpie z reklam, które promują oszustwa finansowe oraz produkty zakazane– mówił.Rozmowa dotyczyła też oszustw w sieci i podszywania się pod twórców finansowych. Dr Świder opowiadał o własnych doświadczeniach – prowadząc profil z 100 tys. obserwujących, stał się celem masowych wyłudzeń i kradzieży wizerunku.Powstają profile, które kopiują moje zdjęcia, moje posty i kontaktują się z moimi odbiorcami. To zjawisko masowe – przez kilka lat powstało około 200–300 takich kont– stwierdził gość Magdaleny Uchaniuk.Według Świdra technicznie można byłoby łatwo te fałszywe konta blokować, ale Big Tech nie ma interesu, by to robić.„To walka z wiatrakami. Najważniejsza jest ostrożność”Świder podkreślał, że zgłaszanie profili niczego nie rozwiązuje, bo pojawiają się nowe. Wskazuje na brak skutecznych narzędzi państw – oszuści działają z krajów poza UE i bez trudu ukrywają lokalizację.To jest bardzo trudne do ścigania. Najwięcej mogłaby zrobić Unia, ale jeśli zależymy od USA pod względem bezpieczeństwa, to Amerykanie mają ogromną siłę przetargową– ocenił. Dlatego podkreśla, że „dzisiaj najważniejsza linia obrony to ostrożność użytkownika; sprawdzać profile, nazwy, liczbę obserwujących, bo inne mechanizmy zawodzą.”Zapytany o sytuację w Polsce, Świder przyznaje wprost, że "tego typu oszustwa są bardzo trudne do znalezienia, ponieważ wiele działań jest prowadzonych spoza Europy, przez VPN-y, mafia działa globalnie.Podaje przykład Turcji:„Turcja wyłączyła Instagram na trzy dni i wymusiła dostosowanie algorytmów. Da się. Ale w Europie byłoby to trudne politycznie.”Wniosek jest gorzki: UE była nadzieją na silne regulacje, ale USA i Big Techy skutecznie rozmywają przepisy, a Europa staje się jedynie „rynkiem do zarabiania”.

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

Chodzisz po górach? Czekasz na weekend, byle tylko wyrwać się w Tatry, Bieszczady, Beskidy? Chcesz zaliczyć Koronę Gór Polskich? Ta rozmowa jest dla Ciebie.Gdy wydawało się, że w kwestii map nie da się zrobić już niczego nowego, zza horyzontu wyłania się Sharpmap. Stworzona przez Wojciecha Gronia i zespół ekspertów, mapa ta zdobyła prestiżowy tytuł Cyfrowej Mapy Roku 2025.Czym wyróżnia się Sharpmap? Jak pomoże w planowaniu wędrówek? Czy zwiększy nasze bezpieczeństwo w górach? Tego dowiesz się z naszej rozmowy z Wojciechem Groniem, współtwórcą Sharpmap.

W świecie weird fiction słowo „normalność” traci sens. Wojciech Gunia i Daria Chibner rozmawiają o tym, jak ten gatunek przekracza granice rzeczywistości i wyobraźni, odsłaniając głębokie zakamarki ludzkiego umysłu.Podcast powstał we współpracy z internetową księgarniąNexto, dystrybutorem e-booków, audiobooków i prasy.Kup subskrypcję „Rzeczpospolitej” pod adresem: https://czytaj.rp.pl

In this episode, we explore the profound wisdom that lives in the dark. Sjanett sits down with Ananda-Jey Wojciech, founder of The Ultimate Darkness Retreat in Poland, to talk about what happens when you turn off all the lights — literally and metaphorically. What remains when your senses slow down, and there is nothing left to distract you? Ananda-Jey shares how darkness can be both confronting and deeply healing. In the absence of external light, you meet yourself — and discover your own inner luminosity. Together, they discuss silence, surrender, the body's intelligence, and how transformation unfolds when you stop trying to control it. A conversation about trust, stillness, and finding home within yourself. What touched you most in this episode? Share your reflection with us. Learn more:

Ostatnie dziesięciolecia przyniosły nam bezprecedensowy wzrost gospodarczy, równolegle jednak w mentalności społecznej dokonały rewolucyjnych zmian. Wolny wybór, będący złotym cielcem współczesnego społeczeństwa, dotknął także decyzji o założeniu rodziny. Powodzenie propagandy antynatalistycznej w mediach nie bierze się więc znikąd. Wielu rodziców – czasem zupełnie otwarcie i szczerze – zaczyna podkreślać, że wychowanie dzieci może być najbardziej wymagającym przedsięwzięciem w życiu. Nie krytykując słusznego uderzania w antynatalizm, pokuśmy się o sformułowanie punktu wyjścia do dalszej dyskusji.Pozostałe artykuły możesz czytać na

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

Nagrania homilii i kazań wygłoszonych w parafii WNMP w Opolu Gosławicach

Should weed be legalised? What about heroin? Set aside any previously held opinions and prepare a far-out trip! In the final episode of 'Who Does It Best?' producer Wojciech is taking us across the landscape of Europe's drug policies. From 90s Portugal to the coffee shops of Amsterdam to a little pit stop in Uruguay(!), we're taking a deep dive into which policies are the sanest and safest on offer.   MASSIVE THANKS: We want to give a HUGE shoutout to everyone who made this series possible. Our generous crowdfunders hit our goal within two months, making it possible for us to do extensive reporting fully independently. Our hearts are beyond full. Thank you.   BOOST THE SHOW: If you liked the series and want to help us spread the good word, we've prepared some social media posts that you can download and share. Here they are! We'd be eternally grateful if you influenced your followers with our snappy graphics ✨   DON'T QUIT WHILE YOU'RE AHEAD: If you're feeling inspired to support The Europeans' ongoing work, please go to patreon.com/europeanspodcast. You can drop us a few euros or dollars or francs or crowns or whatever the heck ya got.   Additional resources for this episode:  Research on Portugal's decriminalization success story Amsterdam's drop-in center AMOC Zuid    Written, reported and produced by: Wojciech Oleksiak Editor: Jasmin Baoumy  Editorial support: Dominic Kraemer, Katz Laszlo, Katy Lee, Morgan Childs Sound design: Jesse Lou Lawson Mixing and mastering: Wojciech Oleksiak Music and SFX: Jim Barne, Epidemic, FreeSound.org Artwork: RTiiiKA   Thanks to everyone who sat down with Wojciech to share their expertise, including Tom Decorte, Katrin Schiffer, Annika Apfel, Malu Salazar, Cedric Chervet, Adam Nowotarski, Peter Sarosi, Ferry, the De Barones crew, Reinoud van Delft, Gośka, Yahya, Leonie, AMOC clients Bouhz and Damian, Breda's coffeeshop owners. Special thanks go to Leonie, Tom, Łukasz and Michał.   Stay safe out there! YouTube | Bluesky | Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | Mastodon⁠⁠⁠⁠⁠⁠⁠⁠⁠ | hello@europeanspodcast.com   00:00:43 Intro: Rockstar life and drugs 00:09:55 Act I: Soft drugs, tolerance and the myth of legal weed 00:23:15 Act II: You gotta regulate that thing! 00:30:43 Act III: Total decriminalization 00:49:05 Act IV: Legalise everything, regulate everything

O zawikłanej teorii kwantowego splątania oraz perypetiach fizyków parających się badaniami fundamentalnymi opowiada dr Wojciech Krzemień z Narodowego Centrum Badań Jądrowych.

☘️

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

We're taking a momentary break from “Who Does It Best?” to take a trip to Serbia with producer Wojciech Oleksiak. Wojciech was on the ground in Novi Sad last weekend to report from the massive demonstration marking the one-year anniversary of the tragic accident at the city's railway station.  And if you're not following this story, you should be. Much of what's happening in Serbia is a heartening example of how peaceful demonstrations can really move the needle, even in places where the political situation looks bleak. And Serbia's leadership has been following a playbook that is increasingly common across Europe and the rest of the world. Even if you don't live under an illiberal democracy…you might want to get familiar with how they take shape. If you're interested to hear more on this evolving story, check out our episode from earlier this year called “Is real change coming to Serbia?”  We'll be back with the final episode of “Who Does It Best?” on Friday. (Wojciech has had a busy week.)  This podcast was brought to you in cooperation with Euranet Plus, the leading radio network for EU news. But it's contributions from listeners that truly make it all possible—we could not continue to make the show without you! If you like what we do, you can chip in to help us cover our production costs at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (in many different currencies), or you can gift a donation to a superfan. We'd also love it if you could tell two friends about this podcast. We think two feels like a reasonable number. Reported, produced, mixed, and mastered by Wojciech Oleksiak. Editorial support by Dominic Kraemer and Morgan Childs. Special thanks go to Filip Djordjević and Mila Dragnić.  

Wśród niezliczonych roślin, które nas otaczają, część nadaje się do jedzenia. Jedynie garstka z nich zapisała się w historii. Nie tylko żywiły świat, ale też radykalnie go zmieniły, wpływając na życie setek, a czasem wręcz miliardów ludzi. Rośliny te podróżowały pomiędzy kontynentami, były przyczyną wojen, masowych migracji oraz kształtowania się kultury i zwyczajów niejednego społeczeństwa. Jedna z tych roślin jest dynia, nieodmiennie kojarzona jest z Halloween, chociaż jej korzenie sięgają znacznie głębiej w mrok dawnych dziejów.Wszystkie głosy, które usłyszycie w tym odcinku należą do fizycznych, rzeczywiście istniejących osób i nie zostały wygenerowane maszynowo przez algorytmy. ✅ Wspieraj Brzmienie Świata na Patronite:⁠⁠⁠⁠⁠⁠⁠ https://patronite.pl/brzmienie-swiata⁠⁠⁠⁠

 If you want to understand the full spectrum of AI software, from "straightforward problem-solving tool" to "never-ending slop machine," all you need to do is pay attention to everything Adobe launched at its conference this week. David and Nilay run through the news, which will change how people use Photoshop but also maybe change our social feeds forever. After that, they talk about OpenAI's conversion to a for-profit business, and specifically the truly wild way OpenAI and Microsoft talk about the future of AGI. Finally, in the lightning round, they discuss Brendan Carr, Cybertrucks, the Trump Phone, Ghost Posts, and more. Help us improve The Verge: Take our quick survey at theverge.com/survey. Further reading: ⁠Photoshop and Premiere Pro's new AI tools can instantly edit your work ⁠ ⁠You can tell Adobe Express's new AI assistant to edit designs for you⁠ ⁠Adobe's AI social media admin is here with ‘Project Moonlight' ⁠ ⁠Mark Zuckerberg is excited to add more AI content to all your social feeds⁠ ⁠Meta CEO Mark Zuckerberg defends AI spend: 'We're seeing the returns'⁠ ⁠OpenAI completed its for-profit restructuring — and struck a new deal with Microsoft ⁠  ⁠The next chapter of the Microsoft–OpenAI partnership⁠ ⁠OpenAI lays groundwork for juggernaut IPO at up to $1 trillion valuation | Reuters⁠ ⁠OpenAI has an AGI problem — and Microsoft just made it worse ⁠ ⁠OpenAI made ChatGPT better at sifting through your work information ⁠ ⁠Sam, Jakub, and Wojciech on the future of OpenAI with audience Q&A⁠ ⁠The Kingmaker | WIRED⁠ ⁠Congratulations to the Tesla Cybertruck on its 10th recall.⁠ ⁠Trump℠ Mobile | All-American Performance. Everyday Price. $47.45/Month⁠ ⁠Threads is getting disappearing posts ⁠ ⁠Ads will arrive on Samsung Family Hub smart fridges next month. ⁠ ⁠The FCC is going after broadband nutrition labels. ⁠ ⁠Brendan Carr is a Dummy⁠ ⁠Bending Spoons is buying AOL for some reason ⁠ Subscribe to The Verge for unlimited access to theverge.com, subscriber-exclusive newsletters, and our ad-free podcast feed.We love hearing from you! Email your questions and thoughts to vergecast@theverge.com or call us at 866-VERGE11. Learn more about your ad choices. Visit podcastchoices.com/adchoices

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

To i więcej nauczań można znaleźć również na naszej stronie parakletos.pl.

Wizja uczestnictwa we władzy bardzo zbliża polityków, więc może być tak, że Konfederacja wejdzie do koalicji z PiS-em i utworzy rząd, natomiast myślę, że byłaby to krótka kadencja, wyglądająca bardzo podobnie do tej z czasów współpracy PiS-u, Samoobrony i Ligi Polskich Rodzin - mówił w programie „Rzecz w tym” prof. Wojciech Rafałowski, socjolog polityki z Wydziału Socjologii Uniwersytetu Warszawskiego.Kup subskrypcję „Rzeczpospolitej” pod adresem: https://czytaj.rp.pl

Nowy sezon podcastu „O milimetr do przodu” zaczynamy audycją o rozwoju z Wojciechem Eichelbergerem, terapeutą, psychologiem, doradcą biznesu i autorem bestsellerowych książek. Rozmawiamy o obecnej kondycji psychicznej człowieka. Według terapeuty jako ludzkość jesteśmy na poziomie wyparcia i agresji. Zachwycamy się nieodpowiedzialną konsumpcją usług i dóbr materialnych. Społeczeństwa się infantylizują. Każdy odcinek kończy się apelem gościa. Tym razem Eichelberger apeluje o to, by nie nazywać aktualnej regresji rozwojem.W audycji udział biorą politycy, artyści, działacze, psychiatrzy.  Osoby mające wpływ. Moje zaproszenie przyjęli Pierwsza Dama Jolanta Kwaśniewska, Agnieszka Holland, profesor Bogdan De Barbaro.Masz pytania lub chcesz podzielić się przemyśleniami na temat odcinka? Instagram: @justyna.kopinska.Podcastu „O milimetr do przodu” możesz posłuchać na platformach Spotify, Apple Podcasts oraz YouTube.

Nowy sezon podcastu „O milimetr do przodu” zaczynamy audycją o rozwoju z Wojciechem Eichelbergerem, terapeutą, psychologiem, doradcą biznesu i autorem bestsellerowych książek. Rozmawiamy o obecnej kondycji psychicznej człowieka. Według terapeuty jako ludzkość jesteśmy na poziomie wyparcia i agresji. Zachwycamy się nieodpowiedzialną konsumpcją usług i dóbr materialnych. Społeczeństwa się infantylizują. Każdy odcinek kończy się apelem gościa. Tym razem Eichelberger apeluje o to, by nie nazywać aktualnej regresji rozwojem.W audycji udział biorą politycy, artyści, działacze, psychiatrzy. Osoby mające wpływ. Moje zaproszenie przyjęli Pierwsza Dama Jolanta Kwaśniewska, Agnieszka Holland, profesor Bogdan De Barbaro.Masz pytania lub chcesz podzielić się przemyśleniami na temat odcinka? Instagram: @justyna.kopinska.Podcastu „O milimetr do przodu” możesz posłuchać na platformach Spotify, Apple Podcasts oraz YouTube.

Wojciech Mann zdobył się na szczerość i powiedział w wywiadzie o śmierci: "Boję się, że to za chwilę nastąpi". Nie wiem, czy wiesz, że strach przed śmiercią jest jednym z diabelskich narzędzi szatana, by zabrać Ci radość życia i trzymać Cię w niewoli. Jak można się z tego wyzwolić? #NauczaniePastora #śmierć #straching ----------------------------------------------------

It's been a busy week for European politics, European protests, and European wallabies. In the midst of the madness, we caught up with Kateřina Šafaříková of Czech news outlet Seznam Zprávy, who filled us in on the Czech Republic's recent parliamentary elections. Is the probable next Prime Minister, Andrej Babiš, likely to be an Orbán-esque thorn in the EU's side, or does he just kinda wanna text with Macron? Kateřina shares her thoughts. We also catch up on the protests that Georgia's democratic opposition has been staging against the country's government in Tbilisi and a grassroots victory in Lithuania. If you're moved to learn more about what's going on in Georgia, check out our interview with Anna Gvarishvili in the episode “Is this the end of Georgia's European dream?” You can also follow some of the initiatives and journalists Wojciech recommends: Project 64 https://x.com/64project_ George Melashivili https://x.com/geomel_ge Marika Mikiashvili https://x.com/Mikiashvili_M Anna Gvarishvili https://x.com/AnnaGvarishvili You can discover more of Kateřina Šafaříková's work over here or follow her on Instagram here. This week's Inspiration Station recommendations are the documentary Pianoforte and the book Dream Count by Chimamanda Ngozie Adichie, courtesy of Patreon member Pia.  Brace yourselves if you decide you do indeed want to hear the now former Lithuanian minister for culture singing on an episode of the Voice. This podcast was brought to you in cooperation with Euranet Plus, the leading radio network for EU news. But it's contributions from listeners that truly make it all possible—we could not continue to make the show without you! If you like what we do, you can chip in to help us cover our production costs at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (in many different currencies), or you can gift a donation to a superfan. We'd also love it if you could tell two friends about this podcast. We think two feels like a reasonable number. 00:00:47 Bentornato! 00:04:08 Good Week: Lithuania's cultural sector 00:15:15 Bad Week: Georgian democratic opposition  00:28:11 Interview: Journalist Kateřina Šafaříková on last week's Czech elections 00:47:34 The Inspiration Station: The documentary Pianoforte and the book Dream Count by Chimamanda Ngozie Adichie 00:52:40 Happy Ending: Massive Der Spiegel wallaby scoop! Producers: Morgan Childs and Wojciech Oleksiak Mixing and mastering: Wojciech Oleksiak

Wojciech Fibak — przez lata dżentelmen polskiego sportu, symbol klasy, elegancji i sukcesu. Triumfator turniejów ATP, półfinalista Wimbledonu, reprezentant Polski w Pucharze Davisa. Kolekcjoner sztuki, biznesmen, człowiek salonów, który obracał się wśród elit — od Donalda Trumpa po czołowych artystów: De Niro, Hugh Grant, Mick Jagger. Ale za tą perfekcyjnie skrojoną fasadą kryje się historia, która podzieliła opinię publiczną. Głośny skandal opisany przez „Wprost”, zarzuty o międzynarodowe pośrednictwo w kontaktach z luksusowymi dziewczynami, to moralne dylematy, których echo słychać do dziś. Fibak, choć nigdy nie przyznał się do winy, do dziś mierzy się z cieniem tamtych publikacji. Jak sam dziś odnosi się do tych afer?  Co myśli o współczesnym świecie sportu i o tym, że Iga Świątek „nie daje się lubić”? Czy miliony, które stracił na produkcji „Psów” Pasikowskiego, były ceną za pasję, czy błędem człowieka, który zawsze grał va banque? Jakie były najdroższe obrazy, w które zainwestował? Dlaczego sprzedaje swój dom w Paryżu?  #płatnawspółpraca

This show has been flagged as Explicit by the host. New hosts Welcome to our new hosts: Wojciech, Major_Ursa. Last Month's Shows Id Day Date Title Host 4456 Mon 2025-09-01 HPR Community News for August 2025 HPR Volunteers 4457 Tue 2025-09-02 doodoo deuce Jezra 4458 Wed 2025-09-03 Creating an animation in Powerpoint Dave Hingley 4459 Thu 2025-09-04 How I got into tech Wojciech 4460 Fri 2025-09-05 Arthur C. Clarke Ahuka 4461 Mon 2025-09-08 Battle of the mic's Lee 4462 Tue 2025-09-09 HPR Beer Garden - Intro and Dessert Stouts Kevie 4463 Wed 2025-09-10 Software Freedom Day NJ, briefly. murph 4464 Thu 2025-09-11 Replacing the Trackpad on my Laptop Claudio Miranda 4465 Fri 2025-09-12 Playing Civilization V, Part 3 Ahuka 4466 Mon 2025-09-15 HPR Music project - Walking tune to(wards) a friend FredBlack 4467 Tue 2025-09-16 A small Odoo usage intro and a larger technical bit Jeroen Baten 4468 Wed 2025-09-17 AI Trap and Fix Archer72 4469 Thu 2025-09-18 Disagree With Me - 3 Statements About Life Living Antoine 4470 Fri 2025-09-19 HPR is twenty years old today. Lee 4471 Mon 2025-09-22 Ti-82 Makes Music and Password Manager operat0r 4472 Tue 2025-09-23 Cheap Yellow Display Project: Introduction to the Cheap Yellow Display Trey 4473 Wed 2025-09-24 HPR Beer Garden 2 - Session IPA Kevie 4474 Thu 2025-09-25 Hacker Poetry - 001 Major_Ursa 4475 Fri 2025-09-26 The true audio file for walking tune to(wards) a friend FredBlack 4476 Mon 2025-09-29 Does AI cause brain damage? Trollercoaster 4477 Tue 2025-09-30 doodoo 3 a deuce plus 1 Jezra Comments this month These are comments which have been made during the past month, either to shows released during the month or to past shows. There are 22 comments in total. Past shows There are 4 comments on 4 previous shows: hpr4393 (2025-06-04) "Journal like you mean it." by Some Guy On The Internet. Comment 1: Archer72 on 2025-09-01: "Journaling" hpr4442 (2025-08-12) "Orthopedagogiek - what it is." by Manon. Comment 4: Manon Fallon on 2025-09-07: "Thank you" hpr4445 (2025-08-15) "doodoo one" by Jezra. Comment 3: Windigo on 2025-09-03: "Singular vs plural functions" hpr4453 (2025-08-27) "IPv6 for Luddites" by beni. Comment 5: Paulj on 2025-09-09: "Fantastic show - thank you" Comment 6: Dave Morriss on 2025-09-09: "I was surprised to find that my ISP offers IPv6" This month's shows There are 18 comments on 10 of this month's shows: hpr4456 (2025-09-01) "HPR Community News for August 2025" by HPR Volunteers. Comment 1: candycanearter07 on 2025-09-01: "show doubt"Comment 2: أحمد المحمودي on 2025-09-12: "Pronouncing my name"Comment 3: Ken Fallon on 2025-09-16: "Can I have an example" hpr4459 (2025-09-04) "How I got into tech" by Wojciech. Comment 1: Archer72 on 2025-09-01: "First show"Comment 2: Antoine on 2025-09-04: "Welcome! "Comment 3: Henrik Hemrin on 2025-09-04: "Thanks and welcome"Comment 4: Andrew on 2025-09-04: "Excellent first show..."Comment 5: paulj on 2025-09-09: "Welcome, and thanks!" hpr4461 (2025-09-08) "Battle of the mic's" by Lee. Comment 1: candycanearter07 on 2025-09-12: "Interesting dive into a topic not thought about often!" hpr4462 (2025-09-09) "HPR Beer Garden - Intro and Dessert Stouts " by Kevie. Comment 1: T.A.Spinner on 2025-09-13: "Your thoughts on hefeweizens?" hpr4466 (2025-09-15) "HPR Music project - Walking tune to(wards) a friend" by FredBlack. Comment 1: candycanearter07 on 2025-09-25: "unique idea for a show!" hpr4470 (2025-09-19) "HPR is twenty years old today. " by Lee. Comment 1: quvmoh on 2025-09-20: "congrats"Comment 2: ClaudioM on 2025-09-26: "Happy 20th Anniversary!" hpr4471 (2025-09-22) "Ti-82 Makes Music and Password Manager" by operat0r. Comment 1: candycanearter07 on 2025-09-25: "TI calc history" hpr4472 (2025-09-23) "Cheap Yellow Display Project: Introduction to the Cheap Yellow Display " by Trey. Comment 1: Archer72 on 2025-09-23: "Following the series" hpr4473 (2025-09-24) "HPR Beer Garden 2 - Session IPA" by Kevie. Comment 1: Ken Fallon on 2025-09-24: "FLOSS Beer Tracker " hpr4476 (2025-09-29) "Does AI cause brain damage?" by Trollercoaster. Comment 1: Trey on 2025-09-29: "Excellent episode"Comment 2: Trollercoaster on 2025-09-30: "Re: Excellent episode" Mailing List discussions Policy decisions surrounding HPR are taken by the community as a whole. This discussion takes place on the Mailing List which is open to all HPR listeners and contributors. The discussions are open and available on the HPR server under Mailman. The threaded discussions this month can be found here: https://lists.hackerpublicradio.com/pipermail/hpr/2025-September/thread.html Events Calendar With the kind permission of LWN.net we are linking to The LWN.net Community Calendar. Quoting the site: This is the LWN.net community event calendar, where we track events of interest to people using and developing Linux and free software. Clicking on individual events will take you to the appropriate web page.Provide feedback on this episode.

Czy są na świecie miejsca, które zachwyciły Wojciecha Manna? Czy w muzyce wydarzyło się coś ważnego od czasów Beatlesów? Z jakimi ludźmi najchętniej przebywa Wojciech Mann?Wojciech Mann: To był ciepły dzień. Miałem otwartą szybę w samochodzie i nagle poczułem, że wszystko jest na miejscu. To było niemal uniesienie. ***GDZIE TERAZ ZNAJDĘ INNE CYKLE „TYGODNIKA”?Rozwijamy nasz podkast, dotychczasowe cykle przenosimy do osobnych kanałów. Wyszukaj i zasubskrybuj te podkasty:Podkast Tygodnika Powszechnego – Spotify | Apple Podcasts | RSSTygodnik Powszechny: Nauka –Spotify | Apple Podcasts | RSS (znajdziesz tam dotychczasowe cykle „Miłego antropocenu!” i „Jeszcze inna przyszłość”)Tygodnik Powszechny: Kultura –Spotify | Apple Podcasts | RSS (cykle „Lato z Mannem”, „Ciekawe, co czyta”, „Pod kopułą” i „Własny pokój”)Jagielski Story – Spotify | Apple Podcasts | RSSSzkoła uczuć – Spotify | Apple Podcasts | RSS***„Lato z Mannem” to cykl w Podkaście Tygodnika Powszechnego: rozmowy o książkach, literaturze i kulturze. Z Wojciechem Mannem rozmawia Katarzyna Kubisiowska.Muzyka i montaż: Michał WoźniakFotografie: Grażyna MakaraPartnerem cyklu jest Pekao Towarzystwo Funduszy Inwestycyjnych.Jeśli podobają Ci się nasze tematy, zapraszamy po więcej na serwis www.tygodnikpowszechny.pl. Dostęp do serwisu online „Tygodnika Powszechnego” to wartościowe artykuły tworzone przez najlepszych i nagradzanych autorów i autorki, a nie przez algorytmy. To bieżące i ponadczasowe treści o społeczeństwie, kulturze, świecie i duchowości, opisujące rzeczywistość z wielu perspektyw, unikające uproszczeń i krzykliwych narracji. Wierzymy, że w ten sposób świat można zrozumieć – i naprawić. Dlatego piszemy odpowiedzialnie, z szacunkiem i nadzieją. TygodnikPowszechny.pl to miejsce w sieci, które Cię szanuje.

There's no denying it's been a pretty dark week, but we've got a couple of bright spots for you. What could be a better job than dreaming up ways that Europe could be improved? That's what this week's guest, Johanna Fabrin, does each day at the Copenhagen think tank 21st Europe. Ahead of our miniseries Who Does It Best, Dominic sat down with Johanna to talk about the group's “blueprints” for the continent, the importance of optimism, and who, exactly, is going to pay for a fantasy train system that links all of Europe together like a massive metro line.  And not to be too negative, but…we decided it was a pretty Bad Week for basically all of the western world, thanks to the Russian drone incursion into Poland and Romania. But! It was a Good Week (er, a marginally, “meekly” better week) for the European Union, which is finally—finally—taking some overdue action regarding the war in Gaza. Did Ursula von der Leyen tune into our episode from a couple of weeks ago? We suspect yes.  You can learn more about what 21st Europe is up to on their website and on Instagram. Also mentioned in this episode: Simply Shada, the new Substack created by the brilliant former Europeans guest Shada Islam and the interview with Finland's President Alexander Stubb.  This week's Inspiration Station recommendations are visiting countries in transition/The Wojciech Oleksiak Dua Lipa Tour of Pristina* and the David Szalay novel Flesh. *Restrictions apply, see Wojciech for details This podcast was brought to you in cooperation with Euranet Plus, the leading radio network for EU news. But it's contributions from listeners that truly make it all possible—we could not continue to make the show without you! If you like what we do, you can chip in to help us cover our production costs at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (in many different currencies), or you can gift a donation to a superfan. We'd also love it if you could tell two friends about this podcast. We think two feels like a reasonable number. Timestamps 00:00:47 Intro: Is it just us or are we all feeling like half-deflated balloons? 00:03:17 Bad Week: Russian drone incursion 00:18:05 Good Week: The EU steps up in Gaza war 00:32:21 Interview: Johanna Fabrin of 21st Europe 00:44:11 The Inspiration Station: Wojciech's tour of Kosovo and David Szalay's novel Flesh 00:47:41 Happy Ending: Austrian nun convent break-in Producers: Morgan Childs and Wojciech Oleksiak Mixing and mastering: Wojciech Oleksiak Music: Jim Barne and Mariska Martina YouTube | Bluesky | Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | Mastodon⁠⁠⁠⁠⁠⁠⁠⁠⁠ | hello@europeanspodcast.com

This show has been flagged as Clean by the host. Hello, I'm Wojciech (pronounciation available at https://en.wiktionary.org/wiki/Wojciech ), I'm a nerd from Poland, I work as a software engineer. I've found HPR about a year ago and wanted to record a show since. But life is busy. I'm trying it out, in a supermarket parking lot in my car. This is my second attempt, so we'll see how it works. How I got into tech? In a way I've kind of always been there. At least since I was a child. The story that I like to tell is when I was about 4 years old my cousing launched me Mortal Kombat on his Amiga computer and I got interested. That's my oldest tech related memory. As a kid I've mostly played video games. Mostly on clones of old 8-bit consoles like Atari 2600 or NES, later some unspecified models of Commodore and Schneider computers. I don't even remember what exact models they were. Got my first PC at about 10 years old, it was an Intel 486SX, 12 MB RAM, 850 MB HDD, running Windows 95. Still mostly playing games on the computer but, as it was running Windows, as you maybe know, with Windows come problems. Sometimes user-induced, but not always. Spoiler, it's been over 25 years and this trend continues. Around the same time my sister went to high school and got a Turbo Pascal textbook. This is what really got me interested in programming and that's when my interests and career in software development begun. Since that time I had a very good idea what I want to do in life. I just knew I wanted to work with computers, primarily doing software engineering. I went to a technical university, Wrocław University of Science and Technology. And there I got interested in other computer related things like networking and I also got into digital and analog electronics. Just because I really wanted to go that one level deeper, to learn about how computers work, and electronics in general. I also have other interests, but tech and non-tech related, like for example science fiction literature and I would like to record some shows about those in the future. We shall see. There is one specific story I want to tell, but I think I will save it for October. Why October? Because it is a workplace horror story about... Windows. Well, not really a horror story story, but it was really bizarre and can be described as such. In the meantime I don't want to promise anything. But maybe I will record a show about what I am currently doing at work, which is the topic of audit trail in software applications. But I am chaotic and may do something entirely different. We shall see. I think that's all I want to say today. I would really appreciate if you left some feedback. Was the audio OK, is my English enough, did I speak too fast? English is not my first language and I've noticed over the years that I really tend to speak too fast when using English. And that's it, thank you for listening. Hopefully we'll hear in the future from me. Provide feedback on this episode.

LifeStance therapists Wojciech Seweryn, Ricky Esposito Jr and Jasper Waite join us on this episode to tackle some of the most common myths about male providers in mental health. The conversation explores unconscious biases that often influence a preference for female therapists, along with stereotypes that male therapists may be less empathetic or warm. Wojciech, Ricky, and Jasper share how they build strong therapeutic relationships, the unique strengths they bring to their work, and how they address hesitations from clients who are unsure about seeing a male therapist. They also reflect on the importance of modeling healthy masculinity and emphasize that every therapist—regardless of gender—offers their own individual strengths.

What happens when we stick a thermocouple into a fire? The answer is surprisingly complex and has profound implications for fire safety engineering. In this deep-dive episode, Dr. David Morrisset from Queensland University joins Wojciech to unravel the science of fire measurements that underpins every experiment, test report, and dataset in our field.The conversation reveals a critical truth often overlooked by practitioners: measurements don't capture reality directly - they capture the interaction between our instruments and fire phenomena. When a thermocouple reports a temperature, it's actually measuring its own thermal equilibrium, not necessarily the gas temperature we assume it represents. This distinction becomes crucial when using experimental data to validate models or make engineering decisions.The hosts explore various measurement techniques - from temperature and flow measurements to heat flux gauges and oxygen consumption calorimetry - detailing their underlying principles, practical challenges, and hidden assumptions. David shares fascinating insights from his research, including innovative approaches to extracting meaningful data from noisy mass loss measurements and using high-resolution temperature fields to calculate heat fluxes without traditional gauges.This episode offers essential context for anyone who reads research papers, interprets test reports, or uses experimental data in their practice. By understanding the nuances of how we measure fire phenomena, engineers can better evaluate the quality and applicability of experimental results, recognise their limitations, and ultimately make more informed safety decisions. Whether you're conducting experiments or applying their results, this conversation will transform how you think about the data that drives our field.I've received a bunch of papers from David to share with you, here we go:Data smoothing - particularly around things like the MLR. This is covered in many papers, and you can start with: https://linkinghub.elsevier.com/retrieve/pii/S0379711222000893The "blue light method" was discussed in the podcast with Matt Hoehler from NIST - I came up with the same kind of effect but with PMMA (using black light instead of blue light) - https://doi.org/10.1016/j.firesaf.2025.104425We did some work on characterising the thermal boundary layer generated by gas-fired radiant panels. https://doi.org/10.1016/j.firesaf.2023.104013 In the flame spread work, I did use temperature data to approximate the heat flux acting at the surface https://doi.org/10.1016/j.firesaf.2023.104048----The Fire Science Show is produced by the Fire Science Media in collaboration with OFR Consultants. Thank you to the podcast sponsor for their continuous support towards our mission.

V září 2022 došlo na dně Baltského moře k výbuchu. Někdo odpálil potrubí plynovodu Nord Stream, jenž zásoboval Evropu ruským plynem. Zpráva obletěla celý svět, ale informací bylo zoufale málo – mluvilo se jen o pronajaté jachtě a neznámé posádce. Spekulací přibývalo, naopak oficiální vyšetřování stagnovalo a státy mlčely.Do pátrání se pustil mezinárodní tým novinářů. Jedním z nich byl polský reportér Wojciech Cieśla, který ve spolupráci s novináři z Německa, Dánska a Švédska mapoval trasu jachty Andromeda, odhalil falešné firmy i nastrčené zástupce – a postupně složil mozaiku, jež vedla až ke skupině z Ukrajiny. Klíčová ale byla i nečinnost polských úřadů – a také otázka, koho se snažily chránit.V rozhovoru s Pavlou Holcovou mluví Wojciech Cieśla nejen o detailech práce na jedné z největších evropských kauz posledních let, ale i o profesní chybě, která mu zničila pověst, a rovněž o tom, jak těžké bylo znovu si ji vybudovat. Epizoda o síle novinářské spolupráce, odvaze klást nepohodlné otázky – a o moři, kde některé lodě raději nezapínají navigaci.Protagonista je podcast s Pavlou Holcovou. České znění Petr Gojda a Jiří Slavičinský.Přihlaste se k odběru newsletteru Protagonista ⁠zde⁠ (https://investigace.ecomailapp.cz/public/form/135-944c4287a69f4094fc099a7cf7add962) a buďte mezi prvními, kdo se dozví o nových epizodách a spuštění anglické verze.Podcastová série Protagonista vznikla v roce 2025 v koprodukci české redakce investigace.cz, mezinárodní sítě investigativních novinářů OCCRP, dánské společnosti Dark Riviera a francouzské filmové produkční a distribuční společnosti Sciapode. Série Protagonista je součást projektu War Room Content podpořeného Evropskou unií.

Prof. Wojciech Myślecki komentuje sytuację na polskiej scenie politycznej, dyplomatyczny konflikt między premierem a prezydentem USA oraz rolę Karola Nawrockiego. Czy Polska jest w stanie mówić jednym głosem na arenie międzynarodowej? Co dalej z Koalicją?(00:00) Wstęp(2:33) Rozmowa europejskich przywódców z Donaldem Trumpem. Czy polskie władze są zdolne do prezentowania jednego stanowiska?(12:58) Czy Polska jest w stanie odgrywać poważniejszą rolę na arenie międzynarodowej?(32:34) Czy Karol Nawrocki będzie katalizatorem zmiany?(43:47) Co z Koalicją? Co powstanie w zamian?(51:15) Porozumienie prezydenta z premierem to będzie cud?Mecenasi programu: Inwestuj w fundusze ETF z OANDA TMS Brokers: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://go.tms.pl/UkladOtwartyETF ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠AMSO-oszczędzaj na poleasingowym sprzęcie IT: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amso.pl/Uklad-otwarty-cinfo-pol-218.html⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Novoferm: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.novoferm.pl/⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Zgłoś się do Szkoły Przywództwa Instytutu Wolności:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://szkolaprzywodztwa.pl⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://patronite.pl/igorjanke⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠➡️ Zachęcam do dołączenia do grona patronów Układu Otwartego. Jako patron, otrzymasz dostęp do grupy dyskusyjnej na Discordzie i specjalnych materiałów dla Patronów, a także newslettera z najciekawszymi artykułami z całego tygodnia. Układ Otwarty tworzy społeczność, w której możesz dzielić się swoimi myślami i pomysłami z osobami o podobnych zainteresowaniach. Państwa wsparcie pomoże kanałowi się rozwijać i tworzyć jeszcze lepsze treści. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Układ Otwarty nagrywamy w ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bliskostudio.pl ⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

From the EWTN Studio in Rome, Fr. Wojciech Giertych joins Fr. Mitch to discuss the beginning of the life of grace. its connection to nature, and the effects it has on moral life.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ABM865. CME/MOC/EBAH/NCPD/CPE/AAPA/IPCE credit will be available until July 24, 2026.Staying on Track Toward Better CLL Outcomes: Delivering Effective Sequential Care Guided by Real-World Experience In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Gościem TOK 360 był Wojciech Hermeliński, sędzia Trybunału Konstytucyjnego w stanie spoczynku, były przewodniczący Państwowej Komisji Wyborczej. W rozmowie analizowaliśmy najnowsze sprawozdanie PKW dotyczące wyborów prezydenckich, skalę protestów wyborczych oraz nieprawidłowości przy liczeniu głosów. Czy obecny system wyborczy wymaga reformy? Jakie konsekwencje mogą mieć błędy komisji i czy Sąd Najwyższy stanie na wysokości zadania? Szczery i krytyczny głos eksperta o kulisach polskich wyborów i wyzwaniach dla demokracji.

In this On Location episode during OWASP AppSec Global 2025 in Barcelona, Sean Martin connects with event speaker, Wojciech Dworakowski, to unpack a critical and underexamined issue in today's financial systems: the vulnerability of mobile-only banking apps when it comes to transaction authorization.Wojciech points out that modern banking has embraced the mobile-first model—sometimes at the cost of fundamental security principles. Most banks now concentrate transaction initiation, security configuration, and transaction authorization into a single device: the user's smartphone. While this offers unmatched convenience, it also creates a single point of failure. If an attacker successfully pairs their phone with a victim's account, they can bypass multiple layers of security, often without needing traditional credentials.The discussion explores the limitations of relying solely on biometric options like Face ID or Touch ID. These conveniences may appear secure but often weaken the overall security posture when used without additional independent verification mechanisms. Wojciech outlines how common attack strategies have shifted from stealing credit card numbers to full account takeover—enabled by social engineering and weak device-pairing controls.He proposes a “raise the bar” strategy rather than relying on a single silver-bullet solution. Suggestions include enhanced device fingerprinting, detection of emulators or rooted environments, and shared interbank databases for device reputation and account pairing anomalies. While some of these are already in motion under new EU and UK regulations, they remain fragmented.Wojciech also introduces a bold idea: giving users a slider in the app to adjust their personal balance of convenience vs. security. This kind of usability-driven approach could empower users while still offering layered defense.For CISOs, developers, and FinTech leaders, the message is clear—evaluate your app security as if attackers already know the shortcuts. Watch the full conversation to hear Wojciech's real-world examples, including a cautionary tale from his own family. Catch the episode and learn how to design financial security that's not just strong—but usable.GUEST: Wojciech Dworakowski | OWASP Poland Chapter Board Member and Managing Partner at SecuRing | https://www.linkedin.com/in/wojciechdworakowski/HOST: Sean Martin, Co-Founder at ITSPmagazine and Host of Redefining CyberSecurity Podcast | https://www.seanmartin.comSPONSORSManicode Security: https://itspm.ag/manicode-security-7q8iRESOURCESLearn more and catch more stories from OWASP AppSec Global 2025 Barcelona coverage: https://www.itspmagazine.com/owasp-global-appsec-barcelona-2025-application-security-event-coverage-in-catalunya-spainCatch all of our event coverage: https://www.itspmagazine.com/technology-and-cybersecurity-conference-coverageWant to tell your Brand Story Briefing as part of our event coverage? Learn More